Pfizer leads top-selling pharma forecast — Evaluate report
Pfizer upped its 2022 Covid vaccine guidance by $2 billion last quarter on the heels of its bivalent booster launch. While we’ve yet to see …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
